Drug Profile

Basroparib - ST Pharm

Alternative Names: STP06-1002; STP1002

Latest Information Update: 23 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Korea Research Institute of Chemical Technology; ST Pharm
Class Antineoplastics; Fluorobenzenes; Methyl ethers; Phenyl ethers; Piperazines; Pyrimidinones; Small molecules; Triazoles
Mechanism of Action Tankyrase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours
Preclinical Colorectal cancer

Most Recent Events

05 Jan 2025 Chemical structure information added.
13 Sep 2024 Efficacy and adverse event data from the phase I trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress 2024 (ESMO 2024)
14 Apr 2023 Preclinical development in Colorectal-cancer in South Korea (PO) .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com